PHASE-II EVALUATION OF 4'-EPI-DOXORUBICIN IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA

  • 1 January 1982
    • journal article
    • research article
    • Vol. 66  (9) , 1757-1758
Abstract
4''-Epi-doxorubicin (4''-epi-DX) is a new doxorubicin derivative that is more active than the parent compound against murine sarcoma virus tumors and [mouse] Lewis lung carcinoma and may be less toxic. Thirty-five patients with advanced measurable colorectal carcinoma were treated with 4''-epi-DX (85 mg/m2) every 3 wk. The major toxic effect was leukopenia, < 2000 cells/mm3, in 28% of the patients. One of 29 patients (3%) had a partial response. At this dose and schedule, 4''-epi-DX has minimal activity in colorectal carcinoma.